The effects of viscero-somatic interactions on thalamic mast cell recruitment in cystitic rats.
Mast cells accessing the brain parenchyma through the blood-brain barrier in healthy animals are limited to pre-cortical sensory relays - the olfactory bulb and the thalamus. We have demonstrated that unilateral repetitive stimulation of the abdominal wall generates asymmetry in midline thalamic mast cell (TMC) distribution in cyclophosphamide-injected rats, consisting of contralateral side-prevalence with respect to the abdominal wall stimulation. TMC asymmetry 1) was generated in strict relation with cystitis, and was absent in disease-free and mesna-treated animals, 2) was restricted to the anterior portion of the paraventricular pars anterior and reuniens nuclei subregion, i.e., the rostralmost part of the paraventricular thalamic nucleus, the only thalamic area associated with viscero-vagal and somatic inputs, via the nucleus of the solitary tract, and via the medial contingent of the spinothalamic tract, respectively, and 3) originated from somatic tissues, i.e., the abdominal wall where bladder inflammation generates secondary somatic hyperesthesia leading to referred pain in humans. Present data suggest that TMCs may be involved in thalamic sensory processes, including some aspects of visceral pain and abnormal visceral/somatic interactions.
Dubayle
D
D
CNRS UMR 8119, Neurophysique et Physiologie Université Paris Descartes, UFR Biomédicale, 45 rue des Saints Pères, Paris Cedex 06, France. david.dubayle@univ-paris5.fr
Servière
J
J
Menétrey
D
D
D000344:Afferent Pathways / Q000033:anatomy & histology / Q000276:immunology / Q000503:physiopathology; D000818:Animals; D017776:Autonomic Pathways / Q000033:anatomy & histology / Q000276:immunology / Q000503:physiopathology; D001812:Blood-Brain Barrier / Q000276:immunology; D001921:Brain / Q000033:anatomy & histology / Q000276:immunology / Q000503:physiopathology; D002634:Chemotaxis, Leukocyte / Q000276:immunology*; D003520:Cyclophosphamide / Q000009:adverse effects; D003556:Cystitis / Q000276:immunology* / Q000503:physiopathology; D004195:Disease Models, Animal; D007839:Functional Laterality / Q000502:physiology; D007166:Immunosuppressive Agents / Q000009:adverse effects; D008297:Male; D008407:Mast Cells / Q000166:cytology / Q000276:immunology*; D015080:Mesna / Q000494:pharmacology; D009619:Nociceptors / Q000187:drug effects / Q000276:immunology / Q000503:physiopathology; D010146:Pain / Q000276:immunology* / Q000503:physiopathology; D020011:Protective Agents / Q000494:pharmacology; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D013788:Thalamus / Q000166:cytology / Q000276:immunology* / Q000503:physiopathology; D017833:Visceral Afferents / Q000033:anatomy & histology / Q000276:immunology* / Q000503:physiopathology
D007166:Immunosuppressive Agents; D020011:Protective Agents; D016760:Proto-Oncogene Proteins c-fos; D003520:Cyclophosphamide; D015080:Mesna